Where is Summit Therapeutics (SMMT) Headed According to Analysts?

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best biotech stocks with high potential. In a report released on September 29, Leerink Partners maintained a Sell rating on Summit Therapeutics Inc. (NASDAQ:SMMT) without assigning a price target.

Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings

In addition, Barclays also maintained a Sell rating on Summit Therapeutics Inc. on September 25 with a $13 price target.

However, Asthika Goonewardene from Truist Financial maintained a Buy rating on Summit Therapeutics Inc. the same day, without assigning a price target.

In addition to Asthika Goonewardene, Citi’s Yigal Nochomovitz also expressed bullish sentiments for Summit Therapeutics Inc. in a report released on September 24, assigning the stock a Buy rating with a $35 price target.

Summit Therapeutics Inc. is a biopharmaceutical company that specializes in creating novel medications for infectious and cancerous diseases.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

This article is originally published at Insider Monkey.